PREVALENCE
25 Nov 2020
Trial Summary
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
Acronym:
PREVALENCE
ACTRN/NCT /ethics:
NCT03871816
Scientific title:
Biomarker Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
Sponsor / Cooperative group:
Janssen Research & Development, LLC
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Early detection, diagnosis, prognosis |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | Prostate |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2019-04-22 |
| Anticipated End Date | 2023-09-16 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |